非布司他用法用量

Usage and Dosage: When used to treat patients with hyperuricemia with gout symptoms, the recommended dosage of this product is 40 mg or 80 mg, once a day. The recommended starting dose of this product is 40 mg, and there is no need to consider the effects of food or antacids when administering this product.

Medication for special groups:

No dose adjustment is required in patients with mild or moderate renal impairment. The recommended starting dose of this product is 40 mg once daily. After a dose of 40 mg for two weeks, for patients whose serum uric acid level (sUA) is still higher than 6 mg/dl, the recommended dose is 80 mg.

No dose adjustment is required for patients with mild to moderate hepatic impairment. There are no studies on the use of this product in patients with severe hepatic impairment, so this product should be administered with caution.

Elderly patients: After multiple-dose oral administration of this product to elderly patients (≥65 years old), the Cmax and AUC of febuzoxostat and its metabolites are similar to those in younger patients (18-40 years old). In addition, the percentage decrease in serum uric acid concentration was similar in older and younger subjects. No dose adjustment is required for elderly patients.

Uric acid level: Serum uric acid can be retested after 2 weeks of treatment with this product. The goal of treatment is to reduce and maintain serum uric acid levels below 6 mg/dl.

Febuxostat is a xanthine oxidase (XO) inhibitor that binds to xanthine oxidase through a non-competitive mechanism, inhibits xanthine oxidase activity, inhibits the production of uric acid, and achieves the purpose of reducing acidity. Therefore, it is suitable for the long-term treatment of hyperuricemia with gout symptoms. Not recommended for asymptomatic hyperuricemia. Febuxostat is a newly developed drug. At the same dose, febuxostat has a stronger effect in reducing blood uric acid. Therefore, when it comes to the choice of gout acid-lowering drugs, many patients prefer febuxostat.

Inhibition of xanthine oxidase may increase the blood concentration of drugs metabolized by this enzyme, such as azathioprine, mercaptopurine, and theophylline, resulting in toxicity. Therefore, this drug is prohibited from being used in patients who are taking these three drugs.